- Home
- VCYT vs HCM Comparison
VCYT vs HCM Comparison
Compare VCYT & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- HCM
- Stock Information
- Founded
- VCYT 2006
- HCM 2000
- Country
- VCYT United States
- HCM Hong Kong
- Employees
- VCYT N/A
- HCM N/A
- Industry
- VCYT Medical Specialities
- HCM Biotechnology: Pharmaceutical Preparations
- Sector
- VCYT Health Care
- HCM Health Care
- Exchange
- VCYT Nasdaq
- HCM Nasdaq
- Market Cap
- VCYT 2.9B
- HCM 2.6B
- IPO Year
- VCYT 2013
- HCM N/A
- Fundamental
- Price
- VCYT $48.53
- HCM $14.40
- Analyst Decision
- VCYT Buy
- HCM Sell
- Analyst Count
- VCYT 9
- HCM 1
- Target Price
- VCYT $43.56
- HCM $13.75
- AVG Volume (30 Days)
- VCYT 1.2M
- HCM 36.7K
- Earning Date
- VCYT 11-04-2025
- HCM 08-07-2025
- Dividend Yield
- VCYT N/A
- HCM N/A
- EPS Growth
- VCYT N/A
- HCM N/A
- EPS
- VCYT 0.38
- HCM 0.53
- Revenue
- VCYT $495,141,000.00
- HCM $602,197,000.00
- Revenue This Year
- VCYT $14.52
- HCM N/A
- Revenue Next Year
- VCYT $9.90
- HCM $15.49
- P/E Ratio
- VCYT $125.41
- HCM $5.31
- Revenue Growth
- VCYT 16.41
- HCM N/A
- 52 Week Low
- VCYT $22.61
- HCM $11.51
- 52 Week High
- VCYT $50.71
- HCM $19.50
- Technical
- Relative Strength Index (RSI)
- VCYT 71.15
- HCM 37.64
- Support Level
- VCYT $37.98
- HCM $14.00
- Resistance Level
- VCYT $50.71
- HCM $14.42
- Average True Range (ATR)
- VCYT 2.11
- HCM 0.30
- MACD
- VCYT 0.73
- HCM -0.06
- Stochastic Oscillator
- VCYT 82.09
- HCM 25.34
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About HCM HUTCHMED (China) Limited
HUTCHMED (China) Ltd is an biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.